Pasithea Therapeutics (KTTA) Liabilities and Shareholders Equity (2021 - 2024)
Pasithea Therapeutics (KTTA) has disclosed Liabilities and Shareholders Equity for 4 consecutive years, with $18.6 million as the latest value for Q3 2024.
- Quarterly Liabilities and Shareholders Equity fell 39.21% to $18.6 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $58.7 million through Dec 2024, down 57.14% year-over-year, with the annual reading at $26.1 million for FY2023, 42.19% down from the prior year.
- Liabilities and Shareholders Equity hit $18.6 million in Q3 2024 for Pasithea Therapeutics, up from $17.7 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $53.3 million in Q4 2021 to a low of $17.7 million in Q2 2024.
- Historically, Liabilities and Shareholders Equity has averaged $36.1 million across 4 years, with a median of $38.1 million in 2023.
- Biggest five-year swings in Liabilities and Shareholders Equity: soared 135.75% in 2022 and later tumbled 53.7% in 2024.
- Year by year, Liabilities and Shareholders Equity stood at $53.3 million in 2021, then fell by 15.27% to $45.2 million in 2022, then crashed by 42.19% to $26.1 million in 2023, then fell by 28.64% to $18.6 million in 2024.
- Business Quant data shows Liabilities and Shareholders Equity for KTTA at $18.6 million in Q3 2024, $17.7 million in Q2 2024, and $22.4 million in Q1 2024.